Serial prostate specific antigen screening for prostate cancer: A computer model evaluates competing strategies

Journal of Urology

Volumn 162, Issue 3 I, 1999, Pages 741-748

  Etzioni, Ruth ^a   Cha, Raymond ^a   Cowen, Mark E ^a  

^a NONE

Author keywords

Computer simulation; Cost benefit analysis; Mass screening; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0032833235     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199909010-00032     Document Type: Article

References (35)

1. Optenberg, S. A. and Thompson, I. M. Economics of screening for carcinoma of the prostate. Urol. Clin. N. Amer., 17: 719, 1990.
2. Carter, H. B., Piantadosi, S. and Isaacs, J. T.: Clinical evidence for and implications of the multistep development of prostate cancer. J. Urol., 143: 742, 1990.
3. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostate specific antigen: update 1994. J. Urol., 152: 1358, 1994.
4. Krahn, M. D., Mahoney, J. E., Eckman, M. H., Trachtenburg, J., Pauker, S. G. and Detsky, A. S.: Screening for prostate cancer: a decision analytic view. J.A.M.A., 272: 773, 1994.
5. Barry, M. J., Fleming, C., Coley, C. M., Wasson, J. H., Fahs, M. C. and Oesterling, J. E.: Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: estimating the risks and benefits of an early detection program. Urology, 46: 445, 1995.
6. Coley, C. M., Barry, M. J., Fleming, C., Fahs, M. C. and Mulley, A. G.: Early detection of prostate cancer. Part II: estimating the risks, benefits and costs. Ann. Intern. Med., 126: 468, 1997.
7. Legier, J. M., Feuer, E. J., Potosky, A. L., Merrill, R. M. and Kramer, B. S.: The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States. Cancer Causes Control, 9: 519, 1998.
8. Close, D. R., Kristal, A. R., Li, S., Patterson, R. E. and White, E.: Associations of demographic and health-related characteristics with prostate cancer screening in Washington State. Cancer Epidemiol. Biomark. Prev. 7: 627, 1998.
9. American Cancer Society. Cancer Facts and Figures, pp. 20-24, 1998.
10. Carter, H. B., Epstein, J. I., Chan, D. W., Fozard, J. L. and Pearson, J. D.: Recommended prostate-specific antigen testing intervals for the detection for curable prostate cancer. J.A.M.A. 277: 1456, 1997.
11. Pearson, J. D., Landis, P., Fozard, J. L. and Carter, H. B.: When is PSA testing no longer necessary? J. Urol., part 2, 159: 178, abstract 681, 1998.
12. Etzioni, R. and Thompson, I. M.: Prostate cancer and computer models: background, limitations and potential. Urol. Oncol. 2: 57, 1996.
13. GAUSS Mathematical and Statistical System, version 3.2.18. Maple Valley, Washington, Aptech Systems Inc., 1995.
14. Perez, C. A., Fair, W. R. and Ihde, D.: Carcinoma of the prostate. In: Cancer: Principles and Practice of Oncology. Edited by V. T. DeVita, S. Hellman, and S. A. Rosenberg. Philadelphia: J. B. Lippincott, chapt. 33, pp. 1023-1058, 1989.
15. Etzioni, R., Cha, R., Feuer, E. J. and Davidov, O. Asymptomatic incidence and duration of prostate cancer. Amer. J. Epidemiol., 148: 775, 1998.
16. Cowen, M. E., Chartrand, M. and Weitzel, W. F.: A Markov model of the natural history of prostate cancer. J. Clin. Epidemiol., 47: 3, 1994.
17. National Center for Health Statistics: Vital Statistics of the United States, vol. II. Mortality, part A. DHHS PUB. No. (PHS) 88-1122. Washington, D. C.: U.S. Government Printing Office, 1988.
18. Feuer, E. J., Wun, L. M., Boring, C. C.: Probability of developing cancer. In: Cancer Statistics Review: 1973-1989. Edited by A. B. Miller, L. A. G. Reis and B. R. Hankey. National Cancer Institute, NIH Pub No. 92-2789, pp. 1-8, 1993.
19. Murphy, G. P., Natarajan, N., Pontes, J. E., Schmitz, R. L., Smart, C. R., Schmidt, J. D. and Mettlin, C. The national survey of prostate cancer in the United States by the American College of Surgeons. J. Urol., 127: 928, 1982.
20. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A. and Leiber, M. M.: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. J.A.M.A. 270: 860, 1993.
21. Whittemore, A. S., Lele, C., Friedman, G. D., Stamey, T., Vogelman, J. H. and Orentreich, N.: Prostate-specific antigen as predictor of prostate cancer in black men and white men. J. Natl. Cancer Inst. 87: 354, 1995.
22. SEER 1973-1994 Public Use CD-ROM. U.S. Department of Health and Human Services, 1997.
23. Hakulinen, T.: On long-term relative survival rates. J. Chron. Dis., 30: 431, 1977.
24. Habbema, J. D. F., van Oortmarssen, G. J., Lubbe, J. T. and van der Maas, P. J.: The MISCAN simulation program for the evaluation of screening for disease. Comput. Meth. Prog. Biomed. 20: 79, 1985.
25. Skates, S. J., Hou, Q., Dibbs, E., Chang, Y., Vokonas, P. and Barry, M.: Duration of pre-clinical prostate cancer based on serial PSA data from the VA normative aging study. J. Urol., part 2, 159: 124, abstract 479, 1998.
26. Richie, J. P., Catalona, W. J., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., deKernion, J. B., Ratliff, T. L., Kavoussi, L. R. and Dalkin, B. L.: Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology, 42: 365, 1993.
27. Gann, P. H., Hennekens, C. H. and Stampfer, M. J.: A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. J.A.M.A. 273: 289, 1995.
28. Smith, D. S. and Catalona, W. J.: The nature of prostate cancer detected through prostate-specific antigen based screening. J. Urol., 152: 1732, 1994.
29. Morrell, C. H., Pearson, J. D., Carter, H. B. and Brant, L. J.: Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. J. Amer. Stat. Assn. 90: 45, 1995.
30. Coley, C. M., Barry, M. J., Fleming, C., Fahs, M. C. and Mulley, A. G.: Early detection of prostate cancer. Part II: estimating the risks, benefits and costs. Ann. Intern. Med. 126: 468, 1997.
31. Epstein, J. L, Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathologic and clinical findings to predict tumor extent of nonpalpable (Stage T1c) prostate cancer. J.A.M.A. 271: 368, 1994.
32. Pearson, J. D., Luderer, A. A., Metter, E. J., Partin, A. W., Chan, D. W., Fozard, T. L. and Carter, M. B.: Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. Urology, 48: 4, 1996.
33. Eddy, D. M.: A computer-based model for designing cancer control strategies. NCI Monogr., 2: 75, 1986.
34. Urban, N., Drescher, C., Etzioni, R. and Colby, C.: Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control. Clin. Trials, 18: 251, 1997.
35. Ries, L. A. G., Miller, B. A., Hankey, B. F., Kosary, C. L., Harras, A. and Edwards, B. K.: SEER cancer statistics review 1973-1991: tables and graphs, National Cancer Institute. NIH Pub. No. 94-2789, 1994.